Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital

Orchard Therapeutics has raised $34 million in new capital from the second closing of a securities purchase agreement, extending its cash runway through to mid-2025. The funding will support the advancement of its hematopoietic stem cell (HSC) gene therapy portfolio and preparations for the US launch of OTL-200 for MLD, pending FDA approval. The company expects that this funding will provide imp..

  • format_list_bulleted BS
  • · 2023. 6. 27.
  • textsms

NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering

NRx Pharmaceuticals has announced the completion of its registered direct offering for 9,670,002 shares of common stock at $0.65 per share, resulting in gross proceeds of approximately $6.28 million before deducting placement agent fees and other expenses. The company intends to use net proceeds from the offering for working capital and general corporate purposes, as well as potentially using it..

  • format_list_bulleted BS
  • · 2023. 6. 11.
  • textsms